Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

UCB announces scientific presentations on romosozumab at the annual meeting of the American Society for Bone and Mineral Research 2013

• Five scientific presentations on romosozumab at ASBMR 2013
• Romosozumab is an investigational medicine in phase 3 clinical development for the treatment of osteoporosis in post-menopausal women

Brussels (Belgium), 4th October 2013 – (1730 CEST) – UCB, a global biopharmaceutical company is pleased to announce several scientific presentations on romosozumab at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) 2013 in Baltimore, Maryland, US (October 4th-7th 2013). Romosozumab is an investigational medicine in phase 3 clinical development for the treatment of osteoporosis in post-menopausal women and is not currently approved by any regulatory authority.1,2

“The data presented for romosozumab at the ASBMR annual meeting illustrate UCB’s commitment to the development of new treatments for people living with osteoporosis.” said Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President UCB.

UCB and Amgen are collaborating on the clinical development of romosozumab for the treatment of bone-related conditions.

Following is a guide to the presentations on romosozumab:

1. [1022] Effect of Romosozumab on Lumbar Spine and Hip Volumetric Bone Mineral Density (vBMD) as Assessed by Quantitative Computed Tomography (QCT)
Genant, H.K. et al.
Date/Time: Saturday, October 5th, 2013; 0915-0930
Session Info: Oral presentation

2. [SA0406] Bone Formation Response in Mice During Administration and Following
Re-challenge With an Antibody to Sclerostin
Robinson, M. et al.
Date/Time: Saturday, October 5th 2013; 1145-1150
Session Info: Oral Poster Presentations: Clinical
Date/Time: Saturday, October 5th 2013; 1200-1400
Session Info: Poster Session I & Poster Tours

3. [1069] Acute Increase in Bone Formation Following Sclerostin Antibody Treatment Is Consistent With Activation of Bone Lining Cells in Aged Ovariectomized Rats
Ominsky, M.S. et al.
Date/Time: Sunday, October 6th, 2013; 1600-1615
Session Info: Oral Presentation

4. [SU0411] Retreatment With Sclerostin Antibody Increased Bone Formation and Bone Mass in Ovariectomized Rats
Li, X . et al.
Date/Time: Sunday, October 6th, 2013; 1200-1400
Session Info: Poster Session II

5. [SU0412] Romosozumab (Sclerostin Antibody) Improves Bone Mass and Bone Strength in Ovariectomized Rats After 12 Months of Treatment
Ominsky, M. S. et al.
Date/Time: Sunday, October 6th, 2013; 1200-1400
Session Info: Poster Session II

Notes to Editors
About Osteoporosis3,4,5
Osteoporosis affects many women after menopause and is a disease that weakens bones over time, making them thinner and more likely to break. Post-menopausal women with osteoporosis have a greater risk for breaking a bone. Such a break, or fracture, may be a life-changing event. About one in three women over age 50 will have an osteoporosis-related fracture, and once that happens, the chances of another are much higher. The International Osteoporosis Foundation urges governments worldwide to make osteoporosis a healthcare priority.

About Romosozumab1,2
Romosozumab is a bone-forming agent that inhibits sclerostin. It is currently being studied for its potential to reduce fracture risk in an extensive global phase 3 program. This program includes two pivotal studies evaluating romosozumab against both placebo and active comparator in more than 10,000 women with post-menopausal osteoporosis. UCB and Amgen are collaborating on the development of romosozumab.

For further information
• Antje Witte, Investor Relations UCB
T +32.2.559.9414, antje.witte@ucb.com
• Alexandra Deschner, Investor Relations, UCB
T +32 2 559 9683, alexandra.deschner@ucb.com
• France Nivelle, Global Communications UCB
T +32.2.559.9178, france.nivelle@ucb.com
• Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com
• Eimear O Brien, Global Brand Communications UCB
T +32.2.559.9271, eimear.obrien@ucb.com

References
1. ClinicalTrials.gov Accessed September 2013 from http://clinicaltrials.gov/ct2/show/NCT01631214?term=Romosozumab&rank=
2. ClinicalTrials.gov Accessed September 2013 from http://clinicaltrials.gov/ct2/show/NCT01575834?term=AMG+785&rank=12
3. National Osteoporosis Foundation. “What is Osteoporosis.” Accessed September 2013 from http://www.nof.org/articles/7.
4. International Osteoporosis Foundation.” Facts and Statistics.” Accessed September 2013 from http://www.iofbonehealth.org/facts-statistics#category-16.
5. International Osteoporosis Foundation. "Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges." Accessed September 2013 from http://www.iofbonehealth.org/osteoporosis-european-union-ten-years-progress-and-ongoing-challenges

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

PIPE-PRR-026057-102013


Stay up-to-date on the latest news and information from UCB